

Glaucoma Panel

Panel Gene List: ADAMTS10, ASB10 (GLC1F), BEST1, BMP4, COL4A1, COL8A2, CREBBP, CYP1B1, FBN1, FOXC1, FOXE3, GJA1, ISPD, LMX1B, LTBP2, MAF, MYOC, NTF4, OPA1, OPA3, OPTC, OPTN, PIK3R1, PITX2, PITX3, POMT1, PRSS56, PXDN, RPS19, RRM2B, SBF2, SH3PXD2B, SIX6, TBK1, TMEM126A, TTR, WDR36

Clinical Features:

Glaucoma is a heterogeneous neurodegenerative disorder affecting more than 60 million people worldwide.¹ It is characterized by progressive damage of retinal ganglion cells and optic nerve fibers resulting in visual field loss. Glaucoma is the leading cause of irreversible blindness when untreated.² It can be classified into primary and secondary types. Secondary glaucoma originates from a previous condition, trauma, or inflammation.⁵ The major types of primary glaucoma include primary open-angle glaucoma (POAG), primary congenital glaucoma (PCG), primary angle closure glaucoma (PACG).

Primary open angle glaucoma

POAG is the most common form of glaucoma.¹⁴ It is characterized by an open angle between the iris and the cornea and cupping of the optic nerve head (optic disk).¹⁴ Progressive damage to the optic nerve results in visual field loss.² POAG may occur with increased or normal intraocular pressures.¹ Normal intraocular pressure is referred to as normal-tension glaucoma (NTG). POAG may have juvenile or adult onset. Juvenile onset (JOAG) is associated with high intraocular pressures, visual field loss, and optic disc damage, for which early surgical therapy is required.¹ Multiple genes have been associated with primary open angle glaucoma including *ASB10*, *CYP1B1*, *MYOC*, *NTF4*, *OPTC*, *OPTN*, *TBK1*, *WDR36*.⁶⁻¹³

Primary congenital glaucoma

PCG occurs due to developmental defects of the trabecular meshwork and anterior chamber angle.⁴ It is characterized by elevated intraocular pressure and an enlarged globe (buphthalmos) due to inadequate drainage of aqueous humor.⁴ PCG is present from birth and typically diagnosed within the first year. It is more commonly bilateral (70%) and occurs most often in males (65%).⁴ Tearing, photophobia, corneal edema, and irritability are classic symptoms of disease. Some individuals with severe glaucoma eventually become legally blind while others will have excellent vision later in life.⁴ Substantially better outcomes are observed in individuals with lower intraocular pressures, however, permanent vision loss may occur if untreated.⁴ Variants in the *CYP1B1* gene are the most common genetic cause of PCG. The *LTBP2* gene has also been associated with PCG.⁴

Primary angle closure glaucoma

PACG occurs when disruptions in the anterior segment lead to blockage of the trabecular meshwork.¹⁶ The closed angle between the iris and the cornea prevents appropriate drainage of the aqueous humor.⁵ As a result, individuals experience elevated intraocular pressure.^{5,15} Progression of PACG is preventable to some extent if the angle closure process can be stopped early.¹⁷ Treatments including laser peripheral iridotomy and cataract extraction are recently proving to be effective.¹⁷ While POAG is most common in Europeans and Africans, the majority (80%) of individuals with PACG are from Asia.^{15,16} The molecular mechanisms and genes contributing to PACG remain poorly understood.¹⁷ However, variants in the PRSS56 gene have been associated with PACG.¹⁵

Conditions associated with glaucoma

Anterior segment dysgenesis (ASD) disorders, associated with an approximately 50% risk for glaucoma, are a group of disorders characterized by a range of congenital eye anomalies.¹⁸ These include corneal opacity, iris hypoplasia, malformed irido-corneal angle drainage structure, posterior embryotoxon, iris hypoplasia or rupture, ectopic pupils, and irido-corneal or lens-corneal adhesion.¹⁸ ASD can occur as an isolated ocular anomaly or as a syndrome. In addition, certain combinations of ocular anomalies are recognized as separate diagnostic entities such as Axenfeld-Rieger syndrome, SHORT syndrome, and Peter's anomaly.¹⁸ Genes involved in ASD and associated syndromes include *BMP4*, *CYP1B1*, *FOXC1*, *FOXE3*, *COL4A1*, *PIK3R1*, *PITX2*, *PITX3*, *PXDN*.¹⁸⁻²⁰ Many other genetic conditions associated with glaucoma exist including but not limited to Weill-Marchesani syndrome, Muscle-eye-brain disease, Walker-Warburg syndrome, Nail-patella syndrome, Marfan syndrome, and Rubenstein-Taybi syndrome.²¹⁻²⁴

The glaucoma panel may clarify a clinical diagnosis or identify a genetic diagnosis for glaucoma or a glaucoma-related disorder. If a genetic diagnosis is found, genetic testing and recurrence risk information would be available for at-risk family members. In addition, having an identified genetic diagnosis may or may not impact medical management or treatment of the condition.

Genetics:

Autosomal dominant, autosomal recessive inheritance.

Test Methods:

Using genomic DNA extracted from the submitted specimen, the complete coding regions and splice site junctions of the genes tested are enriched using a proprietary targeted capture system developed by GeneDx for next-generation sequencing with CNV calling (NGS-CNV). The enriched targets are simultaneously sequenced with paired-end reads on an Illumina platform. Bi-directional sequence reads are assembled and aligned to reference sequences

based on NCBI RefSeq transcripts and human genome build GRCh37/UCSC hg19. After gene specific filtering, data are analyzed to identify sequence variants and most deletions and duplications involving coding exons; however, technical limitations and inherent sequence properties effectively reduce this resolution for some genes. Alternative sequencing or copy number detection methods are used to analyze or confirm regions with inadequate sequence or copy number data by NGS. Reportable variants include pathogenic variants, likely pathogenic variants and variants of uncertain significance. Likely benign and benign variants, if present, are not routinely reported but are available upon request.

The technical sensitivity of sequencing is estimated to be >99% at detecting single nucleotide events. It will not reliably detect deletions greater than 20 base pairs, insertions or rearrangements greater than 10 base pairs, or low-level mosaicism. The copy number assessment methods used with this test cannot reliably detect copy number variants of less than 500 base pairs or mosaicism and cannot identify balanced chromosome aberrations. Assessment of exon-level copy number events is dependent on the inherent sequence properties of the targeted regions, including shared homology and exon size.

Test Sensitivity:

Primary open angle glaucoma (POAG) disease-causing genes only explain up to 10% of all cases in the general population.¹⁴ It is likely that the hereditary aspect of most POAG cases are due to combined effects of several genes (polygenic) and environmental interactions.² One of the most common genes associated with POAG is *MYOC*, which accounts for 3-5% of adult-onset POAG cases.⁸ It has been reported that the *CYP1B1*, *NTF4*, *OPTN*, *TBK1*, and *WDR36* genes are associated with POAG in approximately 4.6%, 1.7%, 0-6%, 1.2% and 3.7% of cases, respectively.^{9,11-13} The contribution of the *OPTC* gene to POAG is unknown,¹⁰ while variants in the *ASB10* gene are rare, having only been reported in a small subset of families.^{6,13} The genes leading to PACG remain largely unknown.^{15,17}

In primary congenital glaucoma, the *CYP1B1* gene accounts for approximately 87% of familial cases and 27% of sporadic cases, though some reports have ranged from 20-100% for familial cases and 10-27% for simplex cases.^{3,4} The *LTBP2* gene is reportedly responsible for up to 40% of primary congenital glaucoma cases.⁴

Genes involved in ASD and ASD-related disorders include *BMP4*, *CYP1B1*, *FOXC1*, *FOXE3*, *COL4A1*, *PIK3R1*, *PITX2*, *PITX3*, and *PXDN*.^{18-20, 50} Variants in the *PIK3R1* seem to be the only cause of SHORT syndrome, however, a recently identified loss of function mutation in the *BMP4* gene has been associated with SHORT syndrome in one individual.^{28,29} Variations in the *PITX2* and *FOXC1* have been identified in 16% and 24% of patients with ASD with or without systemic anomalies, respectively.¹⁸ Variants in *CYP1B1*, *FOXE3*, *COL4A1*, *PITX3* are

rare, as they have been seen in few families with glaucoma or glaucoma related conditions.^{18,19, 51}

Disorders in which glaucoma is a feature or potential feature involve variants in the genes *ADAMTS10*, *BEST1*, *COL8A2*, *CREBBP*, *FBN1*, *GJA1*, *ISPD*, *LMX1B*, *LTBP2*, *MAF*, *OPA1*, *OPA3*, *POMT1*, *PRSS56*, *RPS19*, *RRM2B*, *SBF2*, *SH3PXD2B*, *SIX6*, *TMEM126A*, *TTR*.^{21,25-27, 30-49}. The contribution of these genes to glaucoma is generally rare and varies with the phenotype of the individual.

Gene	Protein	Inheritance	Disease Associations
<i>ADAMTS10</i>	A disintegrin-like and metalloproteinase with thrombospondin type 1 motif	AR	Weill-Marchesani
<i>ASB10</i>	Ankyrin repeat and SOCS box-containing protein 10	AD	Primary open angle glaucoma
<i>BEST1</i>	Bestrophin-1	AD	Bestrophinopathy, macular dystrophy, retinitis pigmentosa, vitreoretinopathology
<i>BMP4</i>	Bone morphogenetic protein 4	AD	SHORT syndrome, microphthalmia, orofacial cleft
<i>COL4A1</i>	Collagen type 4 alpha-1	AD	Walker-Warburg syndrome, muscle-eye-brain disease
<i>COL8A2</i>	Collagen type 8 alpha-2	AD	Fuchs endothelial corneal dystrophy, posterior polymorphous corneal dystrophy
<i>CREBBP</i>	Creb-binding protein	AD	Rubenstein-Taybi syndrome
<i>CYP1B1</i>	Cytochrome P450 subfamily 1, polypeptide 1	AR	Primary congenital glaucoma, primary open angle glaucoma, anterior segment dysgenesis
<i>FBN1</i>	Fibrillin	AD	Marfan syndrome, Weill-Marchesani syndrome
<i>FOXC1</i>	Forkhead box C1	AD	Anterior segment dysgenesis, Axenfeld-Reiger syndrome
<i>FOXE3</i>	Forkhead box E3	AR	Anterior segment dysgenesis, cataracts, anophthalmia
<i>GJA1</i>	Gap junction protein, alpha-1	AD/AR	Oculotendodigital dysplasia, palmoplantar keratoderma, hypoplastic left heart syndrome
<i>ISPD</i>	Isoprenoid synthase domain-containing protein	AR	Muscle-eye-brain disease, muscular dystrophy-dystroglycanopathy
<i>LMX1B</i>	LIM-homeobox transcription factor 1, beta	AD	Nail-Patella syndrome

Gene	Protein	Inheritance	Disease Associations
<i>LTBP2</i>	Latent transforming growth factor-beta-binding protein 2	AR	Primary congenital glaucoma, Weill-Marchesani syndrome
<i>MAF</i>	Avian musculoaponeurotic fibrosarcoma oncogene homolog	AD	Ayme-Gripp syndrome, cataracts
<i>MYOC</i>	Myocilin	AD	Primary open angle glaucoma
<i>NTF4</i>	Neurotrophin 4	AD	Primary open angle glaucoma
<i>OPA1</i>	Optic atrophy type 1 gene	AD	Optic atrophy, Behr syndrome
<i>OPA3</i>	Optic atrophy type 3 gene	AD	Optic atrophy with cataract, 3-methylglutaconic aciduria
<i>OPTC</i>	Opticin	AD	Primary open angle glaucoma
<i>OPTN</i>	Optineurin	AD	Primary open angle glaucoma
<i>PIK3R1</i>	Phosphatidylinositol 3-kinase regulatory subunit 1	AD	SHORT syndrome, Immunodeficiency 36
<i>PITX2</i>	Paired-like homeodomain transcription factor 2	AD	Anterior segment dysgenesis, Axenfeld-Rieger syndrome
<i>PITX3</i>	Paired-like homeodomain transcription factor 2	AD	Anterior segment dysgenesis, cataracts
<i>POMT1</i>	Protein O-mannosyltransferase 1	AR	Muscle-eye brain disease, Muscular dystrophy-dystroglycanopathy, Walker-Warburg syndrome
<i>PRSS56</i>	Protease, serine, 56	AR	Microphthalmia, primary angle-closure glaucoma
<i>PXDN</i>	Peroxidasin, homolog of drosophila	AR	Anterior segment dysgenesis
<i>RPS19</i>	Ribosomal protein S19	AD	Diamond-Blackfan anemia
<i>RRM2B</i>	Ribonucleotide reductase, M2 B	AD	Progressive external ophthalmoplegia, AR mtDNA depletion syndrome
<i>SBF2</i>	Set-binding factor 2	AR	CMT4B2
<i>SH3PXD2B</i>	SH3 and PXZ domains-containing protein 2B	AR	Frankt-ter Haar syndrome
<i>SIX6</i>	Sine oculis homeobox homolog of drosophila	AR	Optic disc anomalies, retinal and macular dystrophy
<i>TBK1</i>	Tank-binding kindase 1	AD	Primary open angle glaucoma, frontotemporal dementia, ALS
<i>TMEM126A</i>	Transmembrane protein 126A	AR	Optic atrophy
<i>TTR</i>	Transthyretin	AD	Familial amyloidotic polyneuropathy
<i>WDR36</i>	WD repeat-containing protein 36	AD	Primary open angle glaucoma

References:

1. Abu-Amero et al., (2015) *Int J Mol Sci* 16(12):28886-911 26690118
2. Liu et al., (2017) *Medicine (Baltimore)* 96(26):e7291 (PMID: 28658128)
3. Abdolrahimzadeh et al., (2015) *Biomed Res Int* 2015:781294 (PMID: 26451378)
4. Abu-Amero et al., *GeneReviews*® 1993-2017: <https://www.ncbi.nlm.nih.gov/books/NBK1135/>
5. Cascella et al., (2015) *Biomed Res Int* 2015:321291 (PMID: 26451367)
6. Pasutto et al., (2012) *Hum. Mol. Genet.* 21(6):1336-49 (PMID: 22156576)
7. Reis et al., (2016) *Mol. Vis.* 22:1229-1238 (PMID: 27777502)
8. Aroca-Aguilar et al., (2008) *Molecular Vision* 14:2097-108 (PMID: 19023451)
9. Pasutto et al., (2009) *Am. J. Hum. Genet.* 85(4):447-56 (PMID: 19765683)
10. Acharya et al., (2007) *BMC Mol. Biol.* 8:21 (PMID: 17359525)
11. Aung et al., (2005) *Investigative Ophthalmology & Visual Science* 46 (8):2816-22 (PMID: 16043855)
12. Awadalla et al., (2015) *Am. J. Ophthalmol.* 159(1):124-30.e1 (PMID: 25284765)
13. Janssen et al., (2013) *Prog Retin Eye Res* 37:31-67 (PMID: 24055863)
14. Kwon et al., (2009) *N. Engl. J. Med.* 360(11):1113-24 (PMID: 19279343)
15. Jiang et al., (2013) *Mol. Vis.* 19:2217-26 (PMID: 24227917)
16. Vithana et al., (2012) *Nat. Genet.* 44(10):1142-1146 (PMID: 22922875)
17. Sun et al., (2017) *Prog Retin Eye Res* 57:26-45 (PMID: 28039061)
18. Reis et al., (2011) *Curr Opin Ophthalmol* 22(5):314-24 (PMID: 21730847)
19. Micheal et al., (2016) *PLoS ONE* 11(7):e0159259 (PMID: 27409795)
20. Schroeder et al., (2014) *Clin. Genet.* 86(3):292-4 (PMID: 23980586)
21. Morales et al., (2009) *Am. J. Hum. Genet.* 85 (5):558-68 (PMID: 19836009)
22. Sparks et al., (1993-2017) *GeneReviews*® <https://www.ncbi.nlm.nih.gov/books/NBK1291/>
23. Ghoumid et al., (2015) *European Journal Of Human Genetics : Ejhg* : (PMID: 25898926)
24. Wiczorek et al., (2009) *Am. J. Med. Genet. A* 149A (12):2849-54 (PMID: 19938080)
25. Tsilou et al., (1993-2017) *GeneReviews*® <https://www.ncbi.nlm.nih.gov/books/NBK1114/>
26. Krämer et al., (2000) *Eur. J. Hum. Genet.* 8(4):286-92 (PMID: 10854112)
27. White et al., (2000) *Hum Mut* 15(4):301-8 (PMID: 10737974)
28. Dymant et al., (2013) *American Journal Of Human Genetics* 93 (1):158-66 (PMID: 23810382)
29. Reis et al., (2011) *Human Genetics* 130 (4):495-504 (PMID: 21340693)
30. Biswas et al., (2001) *Hum. Mol. Genet.* 10 (21):2415-23 (PMID: 11689488)
31. Milani et al., (2015) *Ital J Pediatr* 41 :4 (PMID: 25599811)
32. Jamsheer et al., (2014) *Gene* 539 (1):157-61 (PMID: 24508941)
33. Roscioli et al., (2012) *Nature Genetics* 44 (5):581-5 (PMID: 22522421)
34. Ghoumid et al. (2016) *Eur. J. Hum. Genet.* 24 (1):44-50 (PMID: 25898926)
35. Liu et al., (2011) *Exp. Eye Res.* 93 (4):331-9 (PMID: 21871452)
36. Huang et al. (2014) *Investigative Ophthalmology & Visual Science* 55 (6):3594-602 (PMID: 24825108)
37. Bosley et al. (2011) *Mol. Vis.* 17 :1074-9 (PMID: 21552501)
38. Reynier et al. (2004) *J. Med. Genet.* 41 (9):e110 (PMID: 15342707)
39. Godfrey et al. (2011) *Cur Op In Genet & Dev* 21 (3):278-85 (PMID: 21397493)
40. Draptchinskaia et al. (1999) *Nature Genetics* 21 (2):169-75 (PMID: 9988267)
41. Fratter et al. (2011) *Neurology* 76 (23):2032-4 (PMID: 21646632)
42. Chen et al. (2014) *Genomics Proteomics Bioinformatics* 12 (5):221-7 (PMID: 25462154)
43. Zrhidri et al. (2017) *Gene* 628 :190-193 (PMID: 28694206)
44. Yariz et al. (2015) *Clin. Genet.* 87 (2):192-5 (PMID: 24702266)
45. Meyer et al. (2010) *Mol. Vis.* 16 :650-64 (PMID: 20405026)
46. Kimura et al. (2003) *Arch. Ophthalmol.* 121 (3):351-6 (PMID: 12617705)
47. Crowley et al. (2014) *Doc Ophthalmol* 129 (1):57-63 (PMID: 24859690)
48. Kuchtey et al. (2013) *Am. J. Med. Genet. A* 161A (4):880-3 (PMID: 23444230)
49. Ali et al. (2009) *American Journal Of Human Genetics* 84 (5):664-71 (PMID: 19361779)
50. Medina-Trillo et al. (2015) *PLoS ONE* 10 (3):e0119272 (PMID: 25786029)
51. Iseri et al. (2009) *Human Mutation* 30 (10):1378-86 (PMID: 19708017)